F
1.00
-0.02 (-1.96%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | FibroBiologics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
1.9
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.88 |
|
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 21.42% |
| 机构持股比例 | 16.75% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| American Institute For Advanced Investment Management, Llp | 31 Dec 2024 | 88,206 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 15.00 (D. Boral Capital, 1,400.00%) | 购买 |
| 中 | 10.00 (900.00%) | |
| 低 | 5.00 (HC Wainwright & Co., 400.00%) | 购买 |
| 平均值 | 10.00 (900.00%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 0.250 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 06 Jan 2026 | 15.00 (1,400.00%) | 购买 | 0.260 |
| 20 Nov 2025 | 15.00 (1,400.00%) | 购买 | 0.325 | |
| HC Wainwright & Co. | 02 Jan 2026 | 5.00 (400.00%) | 购买 | 0.240 |
| 05 Nov 2025 | 5.00 (400.00%) | 购买 | 0.370 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合